Trade-off between severe bleeding and ischaemic events from randomisation to 30 days and from 30 days to 6 months. Kaplan–Meier curves from the AUGUSTUS trial comparing DAT versus TT for the composite outcomes of severe bleeding (fatal, intracranial, or major) or severe ischaemic events (cardiovascular death, stent thrombosis, myocardial infarction, or stroke) from randomisation to 30 days (upper section) and from 30 days to 6 months (lower section). Both Kaplan-Meier curves and absolute risk differences support a risk/benefit ratio favouring a 30-day TT followed by DAT. Modified from Alexander et al.²⁸ Abbreviations: DAT, double antithrombotic therapy; TT, triple therapy.